Redefine Surgery
Redefine Surgery develops a surgical intelligence platform that combines computer-vision navigation with robotics for orthopedic procedures.
Founded
2023Redefine Surgery develops a surgical intelligence platform that combines computer-vision navigation with robotics for orthopedic procedures.
Redefine is a niche challenger in a concentrated category: four global medical device developers of orthopedic surgical robots own roughly 80% of the market by revenue and growth, and each direct alternative carries differentiated hardware, from Mako SmartRobotics' 3D CT-based planning, AccuStop haptics and data analytics to ROSA Robotics' pre- and intra-operative data, VELYS' table-mounted imaging-free resection, CORI's handheld platform and handheld navigation that works alongside surgical robots.
Redefine's edge is architectural rather than incremental: its navigation requires no fiducials or arrays, while the systems it displaces are large, expensive and slow to set up, so competition turns on setup time and footprint rather than on adding another robotic arm.
Source: redefinesurgery.com
Redefine's financing base is concentrated and company-specific: the $10 million raised since its 2023 founding came predominantly from surgeon investors, tying the capital that must carry a platform still advancing toward commercialization to the clinicians it hopes to sell to.
Execution risk sits with a young company: founded in 2023 by Peter, Ignacio and Steve to address challenges across medical devices and technology, it must carry the platform from its current advance toward commercialization into clinical adoption.
Source: redefinesurgery.com
The Redefine Vision System attacks the setup burden of orthopedic robotic surgery rather than adding another robotic arm: trackerless computer-vision navigation needs no fiducials or arrays, registration takes seconds rather than minutes in early lab testing, and compact reusable instruments integrate with robotic adjustment.
That packaging positions it against large incumbent systems: current robotic systems are large, expensive and slow to set up, four global medical device developers own roughly 80% of the orthopedic surgical robot market by revenue and growth, and Redefine offers OEM partners an integration path to codevelop differentiated AI-enabled systems for workflows surgeons already use.
Source: